Advertisement

P02.14 High-plex co-detection of RNA and protein to explore tumor-immune interactions utilizing RNAscope with imaging mass cytometry

April, 04, 2024 | Select Oncology Journal Articles

Background

The next breakthroughs in immuno-oncology will be driven by high-plex tools that decipher the spatial arrangement of different cell types within the tumor microenvironment (TME).

Materials and Methods

Imaging Mass Cytometry™ (IMC™) is a proven tool for the study of complex cellular interactions in the TME. It utilizes CyTOF®technology for simultaneous assessment of 40-plus protein markers at subcellular resolution without spectral overlap or background autofluorescence, thus providing unprecedented insight into the organization and function of the TME. Despite this, some protein targets are challenging to include in IMC as they have very few or no commercial antibodies available. Moreover, although cellular identity can easily be deciphered through detection of protein targets, knowledge of the cell’s transcriptome improves understanding of cellular function and activation state.

Results

Here,we present a robust and reliable workflow that combines the highly sensitive and specific RNAscope™ technology for RNA detection with the multiplexing capability of IMC to visualize key RNA and protein markers in the same tumor samples.

Conclusions

The RNAscopeHiPlexv2 assay was combined with protein detection using IMC to evaluate expression of both RNA and protein targets in formalin-fixed, paraffin-embedded (FFPE) tumor tissue microarray (TMA).

J. Pemberton: A. Employment (full or part-time); Significant; Standard BioTools. S. Kala: A. Employment (full or part-time); Significant; Standard BioTools. A. Dikshit: A. Employment (full or part-time); Significant; Standard BioTools. C. Hupple: A. Employment (full or part-time); Significant; Standard BioTools.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –

Advertisement

LATEST

Advertisement

Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy